Our goal is to translate discoveries made in the laboratory to the patients who will benefit from them, and to do it as quickly as possible.
Select a category from the list below, and contact us at 775-982-5050 for oncology studies or 775-982-2976 for all other studies for more thorough explanation of each study.
Trials that are conducted at Renown Health are reviewed by an Institutional Review Board (IRB), a group of people that reviews human research studies. The Renown Research Office works with several IRBs for research oversight, including:
- University of Nevada, Reno Office of Research Integrity
- Western Institutional Review Board (WIRB)
To discuss a problem or complaint, or ask about your rights as a research participant call us at 775-982-4635 and we would be happy to connect you with the appropriate IRB official.
This is a multinational, multicenter, prospective, randomized, open-label study. Comparing Edoxaban with VKA in subjects with Atrial Fibrillation aged 18 and older having undergone TAVI. Participation will last approximately up to 3 years.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extension
Follow-up Imaging After Thrombolysis - Neurology
We provide education and guidance to help patients make decisions about their care and treatment. Our specially trained research nurses and coordinators will help you understand the process and explain what to expect with each visit. We are committed to bringing the highest quality of cancer care to you and your loved ones.
Renown Health MyAIRVO™2 COPD Pilot
Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 - Infectious Disease
Screening for SARS-CoV-2 Immune Plasma - Infectious Disease
Study of the Treatment and Outcomes in critically ill Patients with COVID-19 (STOP-COVID) - Infectious Disease
A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia – Infectious Disease